Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 327-335

  Chakraborty, Ashok K ^a   Welsh, Allison ^a   Digiovanna, Michael P ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Anti estrogen; Breast cancer; Estrogen receptor (ER); Growth factor receptor tyrosine kinase; Insulin like growth factor I receptor (IGF1R)

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 HYDROXYTAMOXIFEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHA IR3; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TYRPHOSTINS;

EID: 77950691907     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0382-5     Document Type: Article

References (29)

1. 1. Argiris A, Wang C-X, Whalen SG, DiGiovanna MP (2004) Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10:1409-1420. doi: 10.1158/10780432.CCR-1060-02 (Pubitemid 38365236)
2. Wang C-X, Koay DC, Edwards A et al (2005) In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer. Breast Cancer Res Treat 92:251-263. doi: 10.1007/S10549-005-3375-z
3. Baserga R (2004) Targeting the IGF-1 receptor: from rags to riches. Eur J Cancer 40:2013-2015. doi: 10.1016/j.ejca.2004. 06.015
4. 4. Huynh H, Nickerson T, Pollak M, Yang X (1996) Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen. ICI 182780. Clin Cancer Res 2(12):2037-2042 (Pubitemid 27006637)
5. Kato S, Endoh H, Masuhiro Y et al (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494. doi:10.1126/science. 270.5241.1491
6. Lee AV, Jackson JG, Gooch JL et al (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13(5):787-796. doi: 10.1210/ me.13.5787
7. Lee AV, Weng CN, Jackson JG, Yee D (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152(1):39-47. doi: 10.1677/ joe.0.1520039
8. 8. Balañá ME, Labriola L, Salatino M et al (2001) Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20:34-47. doi.:1.0.1.038/sj.on.c.1204050 (Pubitemid 32142336)
9. Balañá ME, Lupu R, Labriola L, Charreau EH, Elizalde PV (1999) Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene 18:6370-6379. doi: 10.1038/sj.onc.1203028
10. Camirand A, Lu Y, Pollak M (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells, Med Sci Monit 8(12):BR521-BR526
11. Camirand A, Zakikhani M, Young F, Pollak M (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7:R570-R579. doi: 10.1186/bcr1028
12. 12. Lu YH, Zi XL, Zhao YH, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptm). J Natl Cancer Inst 93(4): 1852-1857. doi: 10.1093/jnci/93.24.1852 (Pubitemid 34048651)
13. 13. Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65(23): 1118-11128. doi: 10.1158/0008-5472.CAN-04-3841. (Pubitemid 41713383)
14. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183(4):412-417. doi: 10.1002/(SICI) 1096-9896(199712) 183:4<412::AID-PATH944>3.0.CO;2-4
15. Fürsenberger G, Morant R, Senn HJ (2003) Insulin-like growth factors and breast cancer. Onkologie 26:290-294. doi: 10.1159/ 000071627
16. Kahlert S, Neudling S, van Eickels M, Vetter H, Meyer R, Grohe C (2000) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275(24): 18447-1.8453. doi: 10.1074/jbc.M910345199
17. Martin MB, Franke TF, Stoica GE et al (2000) A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141(12):4503-4511. doi: 10.1210/en.141.12.4503
18. Song RX, Barnes CJ, Zhang ZG, Bao YD, Kumar R, Santen RJ (2004) The role of She and insulin-like growth factor I receptor in mediating the translocation of estrogen receptor a to the plasma membrane. Proc Natl Acad Sci USA 101(7):2076-2081. doi: 10.1073/pnas.0308334100
19. 19. Migliaccio A, Di Domenico M, Castoria G et al (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiolreceptor complex in MCF-7 cells. EMBO J 15(6): 1292-1300 (Pubitemid 26093465)
20. ras/Erk pathway by progesterone receptor via crosstalk with estrogen receptor. EMBO J 17(7):2008-2018. doi: 10.1093/emboj/17.7.2008
21. Santen RJ, Jeng MH, Wang JP et al (2001) Adaptive hypersensivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 79((1-5 Speciall Issue SI)): 115-125
22. 22. Song RXD, McPherson RA, Adam L et al (2002) Linkage of rapid estrogen action to MAPK activation by ER alpha-She association and She pathway activation. Mol Endocrinol 16(1):116-127. doi:10.1210/me.16.1.116 (Pubitemid 34044502)
23. Zhang ZG, Maier B, Santen RJ, Song RXD (2002) Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activatioin. Biochem Biophys Res Commun 294(5):926933. doi:10.101.6/S0006-291X(02)00348-0
24. Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393-1396. doi: 10.1016/S0140-6736 (97)10384-10391
25. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744-3748
26. 26. Decensi A, Robertson C, Ballardini B et al (1999) Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer 35(4):596-600. doi: 10.10:16/ S0959-8049(98)00428-6 (Pubitemid 29192968)
27. Ho GH, Ji CY, Phang BH, Lee KO, Soo KC, Ng EH (1998) Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study. Ann Surg Oncol 5(4):361-367. doi: 10.1007/BF02303501
28. 28. Chakraborty AK, Liang K, DiGiovanna MP (2008) Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer, Cancer Res 68:1538-1545. doi:10.1158/0008-5472.CAN-07-5935 (Pubitemid 351346863)
29. 29. Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527, doi: 10,1016/j.ccr.2006.10.008 (Pubitemid 44854747)